Medroxyprogesterone for Amenorrhea: Dosage and Administration

Dosage Recommendations

The American College of Obstetricians and Gynecologists recommends medroxyprogesterone acetate (MPA) 10 mg daily for 12-14 days per month to induce withdrawal bleeding in patients with amenorrhea 1, 2, 3
When used as part of sequential hormone therapy with estradiol, MPA is administered during the last 12-14 days of a 28-day cycle, as recommended by the Endocrine Society 2
For continuous regimens, a lower dose of 2.5-5 mg MPA daily can be used, according to the American College of Obstetricians and Gynecologists 3, 4

For amenorrhea in premature ovarian insufficiency, the North American Menopause Society recommends transdermal estradiol (50 μg daily) administered continuously with MPA 10 mg daily for 12-14 days every 28 days 1, 2
This sequential regimen induces regular withdrawal bleeding, with a reported success rate of 80-93% of women experiencing withdrawal bleeding, as stated by the American College of Obstetricians and Gynecologists 2, 3
Continuous combined regimens (daily estrogen plus daily MPA 2.5-5 mg) can be used when amenorrhea is preferred, with amenorrhea rates increasing progressively over time, reaching 40-73% by 6-12 months, according to the Endocrine Society 4

The Centers for Disease Control and Prevention recommends that absence of withdrawal bleeding after progestin challenge may indicate insufficient endogenous estrogen or endometrial pathology, with a strength of evidence level III 5
For patients requiring contraception alongside treatment for amenorrhea, the World Health Organization recommends combined hormonal contraceptives may be preferable to MPA alone, with a strength of evidence level I 5, 6
In patients with iatrogenic premature ovarian insufficiency, the American Heart Association recommends micronized progesterone may be preferred over MPA due to potentially lower cardiovascular risk, with a strength of evidence level II 3

The Centers for Disease Control and Prevention recommends ruling out pregnancy before initiating therapy if the woman's regular bleeding pattern changes abruptly to amenorrhea 7, 8
The Centers for Disease Control and Prevention suggests that annual clinical review focusing on compliance and symptom control is recommended, although no routine laboratory monitoring is required unless specific symptoms arise 7, 8

The Centers for Disease Control and Prevention advises that amenorrhea induced by DMPA (depot medroxyprogesterone) does not require medical treatment and is not harmful—provide reassurance 7, 8
The Centers for Disease Control and Prevention notes that breakthrough bleeding or spotting may occur but generally decreases with continued use 8